New drug aims to shield kidneys during heart surgery

NCT ID NCT07661940

Not yet recruiting Prevention Sponsor: University of Erlangen-Nürnberg Medical School Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether an experimental drug called SP16 can prevent acute kidney injury in people with chronic kidney disease who are having heart surgery with a heart-lung machine. About 120 participants will be randomly assigned to receive either SP16 or a placebo, and neither they nor their doctors will know which they got. The goal is to see if SP16 reduces kidney damage caused by inflammation and reduced blood flow during surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SP16
What this could lead to: If it works, this could point toward a way to prevent kidney damage during heart surgery in patients with existing kidney problems.
What could go wrong: This is an early Phase 2 trial with only 120 participants, so results may not apply to everyone. SP16 has been tested in only 28 people before, and its effectiveness is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AKI - ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AKI - ACUTE KIDNEY INJURY

Contacts and locations

Locations

Universitätsklinikum Erlangen

Erlangen, Bavaria, 91054, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.